Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-A02587-46 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| GlaxoSmithKline | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases. Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications. The profibrosing properties and data from the SSc literature suggest a possible role of the eosinophils in the process of fibrogenesis of SSc.
it will assess the activation state of blood eosinophils in SSc patients compared to healthy controls (ECP production in vitro, surface activation markers, whole transcriptome array, ..).
it will also study skin eosinophils and their recruitment (extracellular eosinophil granules, eotaxins production in skin, ..)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diffuse SSc | Recruitment of 20 patients with diffuse SSc |
| |
| Limited SSc | Recruitment of 20 patients with limited SSc |
| |
| Healthy subjects | Recruitment of 20 healthy subjects (control) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood test | Diagnostic Test | Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of ECP concentrations in supernatants of eosinophils culture | Eosinophils will be sorted, stimulated in vitro for 2 hours and ECP concentration will be assessed in supernatants | Baseline: one session |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of median fluorescence intensities of several surface markers on blood eosinophils, or comparison of percentages of positive cells among all eosinophils for a given marker (flow cytometry) | MFI/% of CD69, HLA class II, CD9, CD11c, CD44, CCR3, CRTH2, IL-5R on blood eosinophils | Baseline: one session |
Not provided
Inclusion Criteria:
For healthy subjects:
Exclusion Criteria for patients and controls:
Not provided
Not provided
The active line of the Internal Medicine department (> 400 sclerodermic patients) guarantees the recruitment of 20 diffuse forms and 20 limited forms
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Guillaume Lefevre, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Claude Huriez, CHU | Lille | France |
Not provided
| ID | Term |
|---|---|
| D012595 | Scleroderma, Systemic |
| D005355 | Fibrosis |
| ID | Term |
|---|---|
| D003240 | Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012871 | Skin Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D006403 | Hematologic Tests |
| ID | Term |
|---|---|
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, Eosinophils, tissue
| Skin biopsies | Diagnostic Test | In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative) |
|
| Gene expression profiles will be compared between SSc patients and healthy controls (whole transcriptome assay) |
Whole genome, transcriptomic approach (differentially expressed genes will be identified using a fold change cutoff) |
| Baseline: one session |
| In skin biopsies: density of eosinophils, extracellular ECP and MBP deposits (absent in healthy skin), and density of eotaxin-1-producing cells will be assessed in damaged skin and apparently healthy skin of SSc patients | Baseline: one session |
| D013568 | Pathological Conditions, Signs and Symptoms |